Format
Items per page
Sort by

Send to:

Choose Destination

Results: 20

1.

Parkinson disease and Alzheimer disease: environmental risk factors.

Campdelacreu J.

Neurologia. 2014 Nov-Dec;29(9):541-9. doi: 10.1016/j.nrl.2012.04.001. Epub 2012 Jun 14. English, Spanish.

2.

A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease.

Richard IH, McDermott MP, Kurlan R, Lyness JM, Como PG, Pearson N, Factor SA, Juncos J, Serrano Ramos C, Brodsky M, Manning C, Marsh L, Shulman L, Fernandez HH, Black KJ, Panisset M, Christine CW, Jiang W, Singer C, Horn S, Pfeiffer R, Rottenberg D, Slevin J, Elmer L, Press D, Hyson HC, McDonald W; SAD-PD Study Group.

Neurology. 2012 Apr 17;78(16):1229-36. doi: 10.1212/WNL.0b013e3182516244. Epub 2012 Apr 11.

3.

Updates in the medical management of Parkinson disease.

Fernandez HH.

Cleve Clin J Med. 2012 Jan;79(1):28-35. doi: 10.3949/ccjm.78gr.11005. Review.

4.

Exercise for people in early- or mid-stage Parkinson disease: a 16-month randomized controlled trial.

Schenkman M, Hall DA, Barón AE, Schwartz RS, Mettler P, Kohrt WM.

Phys Ther. 2012 Nov;92(11):1395-410. doi: 10.2522/ptj.20110472. Epub 2012 Jul 19.

5.

Genetics of Parkinson disease and other movement disorders.

Kumar KR, Lohmann K, Klein C.

Curr Opin Neurol. 2012 Aug;25(4):466-74. doi: 10.1097/WCO.0b013e3283547627. Review.

PMID:
22772876
6.

Randomized trial of deep brain stimulation for Parkinson disease: thirty-six-month outcomes.

Weaver FM, Follett KA, Stern M, Luo P, Harris CL, Hur K, Marks WJ Jr, Rothlind J, Sagher O, Moy C, Pahwa R, Burchiel K, Hogarth P, Lai EC, Duda JE, Holloway K, Samii A, Horn S, Bronstein JM, Stoner G, Starr PA, Simpson R, Baltuch G, De Salles A, Huang GD, Reda DJ; CSP 468 Study Group.

Neurology. 2012 Jul 3;79(1):55-65. doi: 10.1212/WNL.0b013e31825dcdc1. Epub 2012 Jun 20.

7.

Does vigorous exercise have a neuroprotective effect in Parkinson disease?

Ahlskog JE.

Neurology. 2011 Jul 19;77(3):288-94. doi: 10.1212/WNL.0b013e318225ab66. Review.

8.

Caffeine for treatment of Parkinson disease: a randomized controlled trial.

Postuma RB, Lang AE, Munhoz RP, Charland K, Pelletier A, Moscovich M, Filla L, Zanatta D, Rios Romenets S, Altman R, Chuang R, Shah B.

Neurology. 2012 Aug 14;79(7):651-8. doi: 10.1212/WNL.0b013e318263570d. Epub 2012 Aug 1. Erratum in: Neurology. 2012 Oct 16;79(16):1744.

9.

Parkinson disease.

Park NH.

JAAPA. 2012 May;25(5):73-4. Review. No abstract available.

PMID:
22712157
10.

Exercise and physical therapy in early management of Parkinson disease.

Alonso-Frech F, Sanahuja JJ, Rodriguez AM.

Neurologist. 2011 Nov;17(6 Suppl 1):S47-53. doi: 10.1097/NRL.0b013e31823968ec. Review.

PMID:
22045326
11.

Treatment of Parkinson disease: a 64-year-old man with motor complications of advanced Parkinson disease.

Tarsy D.

JAMA. 2012 Jun 6;307(21):2305-14. doi: 10.1001/jama.2012.4829.

PMID:
22706836
12.

Comparison between proliferative and neuron-like SH-SY5Y cells as an in vitro model for Parkinson disease studies.

Lopes FM, Schröder R, da Frota ML Jr, Zanotto-Filho A, Müller CB, Pires AS, Meurer RT, Colpo GD, Gelain DP, Kapczinski F, Moreira JC, Fernandes Mda C, Klamt F.

Brain Res. 2010 Jun 14;1337:85-94. doi: 10.1016/j.brainres.2010.03.102. Epub 2010 Apr 7.

PMID:
20380819
13.

Managing the patient with newly diagnosed Parkinson disease.

Singer C.

Cleve Clin J Med. 2012 Jul;79 Suppl 2:S3-7. doi: 10.3949/ccjm.79.s2a.01. Review.

14.

Olfactory dysfunction in Parkinson disease.

Doty RL.

Nat Rev Neurol. 2012 May 15;8(6):329-39. doi: 10.1038/nrneurol.2012.80. Review.

PMID:
22584158
15.

Depression in Parkinson disease--epidemiology, mechanisms and management.

Aarsland D, Påhlhagen S, Ballard CG, Ehrt U, Svenningsson P.

Nat Rev Neurol. 2011 Dec 26;8(1):35-47. doi: 10.1038/nrneurol.2011.189. Review.

PMID:
22198405
16.

Large-scale replication and heterogeneity in Parkinson disease genetic loci.

Sharma M, Ioannidis JP, Aasly JO, Annesi G, Brice A, Van Broeckhoven C, Bertram L, Bozi M, Crosiers D, Clarke C, Facheris M, Farrer M, Garraux G, Gispert S, Auburger G, Vilariño-Güell C, Hadjigeorgiou GM, Hicks AA, Hattori N, Jeon B, Lesage S, Lill CM, Lin JJ, Lynch T, Lichtner P, Lang AE, Mok V, Jasinska-Myga B, Mellick GD, Morrison KE, Opala G, Pramstaller PP, Pichler I, Park SS, Quattrone A, Rogaeva E, Ross OA, Stefanis L, Stockton JD, Satake W, Silburn PA, Theuns J, Tan EK, Toda T, Tomiyama H, Uitti RJ, Wirdefeldt K, Wszolek Z, Xiromerisiou G, Yueh KC, Zhao Y, Gasser T, Maraganore D, Krüger R; GEO-PD Consortium.

Neurology. 2012 Aug 14;79(7):659-67. doi: 10.1212/WNL.0b013e318264e353. Epub 2012 Jul 11.

17.

Meta-analysis of early nonmotor features and risk factors for Parkinson disease.

Noyce AJ, Bestwick JP, Silveira-Moriyama L, Hawkes CH, Giovannoni G, Lees AJ, Schrag A.

Ann Neurol. 2012 Dec;72(6):893-901. doi: 10.1002/ana.23687. Epub 2012 Oct 15. Review.

18.

Aspiration and swallowing in Parkinson disease and rehabilitation with EMST: a randomized trial.

Troche MS, Okun MS, Rosenbek JC, Musson N, Fernandez HH, Rodriguez R, Romrell J, Pitts T, Wheeler-Hegland KM, Sapienza CM.

Neurology. 2010 Nov 23;75(21):1912-9. doi: 10.1212/WNL.0b013e3181fef115.

19.

Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline.

Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, Juncos JL, Nutt J, Shoulson I, Carter J, Kompoliti K, Perlmutter JS, Reich S, Stern M, Watts RL, Kurlan R, Molho E, Harrison M, Lew M; Parkinson Study Group.

Arch Neurol. 2002 Oct;59(10):1541-50.

PMID:
12374491
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk